Living with diabetes requires meticulous blood sugar management. Traditional insulin therapies, while effective, often carry ...

Also important is that new types of insulin - ultra-rapid-acting - mean even more choice for personalized treatment. Also, the personalized approach to diabetes management fuels investigations ...

Enrique Conterno, president, Lilly Diabetes said that an ultra-rapid acting insulin would be a "natural fit" in the company's growing portfolio. In September, the Lilly-Boehringer Ingelheim ...

“Ultra-rapid acting insulin is a popular choice for people ... that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare ...

Wockhardt Limited, the global pharmaceutical company, has submitted its indigenously developed fast-acting insulin analog, ASPARAPID, for regulatory approval with India’s Drugs Controller ...

These findings may usher in a new era in diabetes treatment without ... of hypoglycaemia and partly covering the need for fast-acting insulin at mealtime. The combination of these two features ...

Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin ... way in which the FDA's new commissioner Scott Gottlieb ...

insulin conjugates with properties such as NNC2215 hold promise for improving treatment of diabetes by potentially lowering the risk of hypoglycemia and partly covering the need for fast-acting ...

slim X2 insulin pump with Eli Lilly’s ultra-rapid acting insulin, Lyumjev, in the European Union (EU). The compatibility with Lyumjev offers new possibilities in the insulin delivery landscape ...